Last updated: July 10, 2026
ecutive summary
HZNP Finance Limited v. Actavis Laboratories UT, Inc., case no. 17-2149 (Fed. Cir.) centers on generic entry risk for a branded HZNP product tied to asserted Orange Book-listed patents. The appellate record indicates the dispute proceeded through the district court and reached the U.S. Court of Appeals for the Federal Circuit, which reviewed the lower court’s patent infringement and/or invalidity conclusions. The case’s litigation outcome drives whether Actavis can launch “at risk” or whether it is stayed by patent injunctions or settlement terms tied to the asserted patents.
What is HZNP Finance Limited v. Actavis Laboratories UT, Inc. 17-2149 about?
The case caption identifies HZNP Finance Limited as the branded/patent owner and Actavis Laboratories UT, Inc. as the generic applicant-manufacturer facing infringement allegations. The litigation is in the patent infringement genre typical of Hatch-Waxman workflows, where HZNP asserts Orange Book patents against a Paragraph IV (or similar) certification for a generic product.
What patents were at issue in 17-2149?
The case number alone is insufficient to extract the specific patent(s)-at-issue, asserted claims, and the exact judgment appealed from without the underlying appellate docket entries or the Federal Circuit opinion text.
What relief was sought?
Based on the procedural posture (district court judgment appealed to the Federal Circuit), the dispute typically targets:
- Judgment of infringement on asserted claims of the Orange Book patents
- Findings on validity (including anticipation/obviousness) and enforceability
- Potential injunctions or launch stays tied to the adjudicated patents
What did the district court decide before the Federal Circuit appeal in 17-2149?
The appeal in 17-2149 implies one of the following lower-court outcomes, commonly seen in Hatch-Waxman patent cases:
- Liability findings of infringement upheld and invalidity rejected
- Invalidity findings that fully or partially disposed of the asserted claims
- Mixed results requiring claim-by-claim appellate review
How does the Federal Circuit typically review these issues?
Federal Circuit review in generic Hatch-Waxman cases often turns on:
- Legal claim construction (de novo)
- Infringement and obviousness frameworks applied to the record
- Substantial evidence standards for factual findings
- Section 112 issues when raised
What is the status and outcome of HZNP Finance Limited v. Actavis Laboratories UT, Inc. 17-2149?
A litigation outcome summary requires the Federal Circuit disposition (opinion, affirmance, reversal, remand), the judgment date, and the mandate. Those details are not provided in the case identifier alone. Without the disposition text and docket events, a complete and accurate summary of the result cannot be produced.
Which patents protect the HZNP product involved in this dispute?
HZNP’s portfolio includes multiple branded medicines. But the exact protected product, the Orange Book patents asserted, and their expiration schedules are not determinable from the citation “17-2149” alone.
Orange Book listings and patent types in Hatch-Waxman cases
For these disputes, Orange Book patents usually include one or more of:
- Drug substance or active ingredient composition patents
- Drug product formulation patents
- Method-of-use patents tied to approved indications
- Manufacturing or process patents
When does HZNP lose exclusivity for the product in 17-2149?
Exclusivity timelines depend on:
- FDA listed patents’ expiration dates (including pediatric exclusivity if applicable)
- Regulatory exclusivity (e.g., 5-year NCE, 7-year Orphan, 3-year new clinical investigation)
- Settlement-driven effective launch dates
These dates are product-specific and cannot be derived from the case number alone.
What Paragraph IV or biosimilar risk is implicated by 17-2149?
The procedural pattern indicates Hatch-Waxman generic risk (Paragraph IV certifications). Biosimilar risk would require a biologic case and FDA BLA/351(k) context, which cannot be confirmed from the identifier alone.
How do infringement/invalidity findings translate into launch timing?
When patents are held infringed and valid, generic entry is typically barred until expiration or settlement. If patents are held invalid or not infringed, the generic may launch sooner, subject to any remaining asserted patents and any remaining statutory or injunctive constraints.
What settlement or injunction outcomes affect Actavis’ launch plans?
Settlement terms in these disputes commonly govern:
- Timing of launch (at-risk vs. post-expiration)
- Design-around requirements (label carve-outs, formulation changes)
- Royalty or fixed-payment arrangements
- Dismissal or covenant-not-to-sue language
The docket history and any settlement order are required to state these facts accurately.
How strong is the patent estate for the asserted HZNP patents in this case?
Strength depends on:
- Claim scope and construction outcomes
- Prior art used for invalidity
- Whether the Federal Circuit affirmed district court reasoning
- Whether the case involved design-arounds and claim coverage boundaries
No patent list or appellate holding is available from the case identifier provided.
What generic entry risks exist for Actavis and other ANDA filers after 17-2149?
Generic entry risk is driven by:
- Whether asserted patents survived appeal
- Whether any remaining patents still prevent launch
- Whether design-around strategies exist
- Whether co-defendant ANDAs or later filers are bound by the outcome
These depend on the final disposition and the remaining patent landscape, neither of which is available here.
Which companies are challenging or defending HZNP patents in this matter?
The caption identifies two parties. Broader “company involved” analysis (additional ANDA defendants, testifying experts, co-inventors, assignees, or related cases) requires docket and opinion information.
Key takeaways
- Case no. 17-2149 is an HZNP vs. Actavis Hatch-Waxman-style patent infringement dispute that reached the Federal Circuit, meaning it involved a challenge to a district court judgment on patent validity/infringement.
- The specific asserted patents, the district court decision, and the Federal Circuit disposition cannot be stated from the case identifier alone without the underlying opinion/docket text.
- Business impact flows from the Federal Circuit’s outcome: it determines whether Actavis can proceed toward launch and whether other ANDA challengers face a similar patent barrier.
FAQs
1) What did the Federal Circuit hold in HZNP Finance Limited v. Actavis Laboratories UT, Inc., 17-2149?
A complete answer requires the Federal Circuit opinion/disposition details (affirm/reverse/remand) and the judgment date, which are not provided in the case identifier.
2) Were the asserted patents composition, formulation, or method-of-use patents in 17-2149?
That depends on the specific patents listed for the appeal and cannot be determined from “17-2149” alone.
3) Does 17-2149 involve a Paragraph IV certification against an ANDA?
The case posture is consistent with Hatch-Waxman generic patent litigation, but the certification type cannot be confirmed without the case record.
4) What launch timing does 17-2149 affect for Actavis or other generics?
It depends on whether infringement and validity findings were upheld or overturned and whether an injunction or stay remained in force after appeal.
5) Are there related cases with the same patents and parties?
Related litigation depends on the asserted patent numbers and docket history, which are not provided here.
References (APA)
- HZNP Finance Limited v. Actavis Laboratories UT, Inc., No. 17-2149 (Fed. Cir.).
